Mailing Address
Harvard Business School, Wyss House
Soldiers Field Road
Boston, MA 02163

OLIVIA ZHAO

+1 913-271-2380, <u>ozhao@hbs.edu</u> <u>https://o-zhao.github.io/</u> Nationality: USA

Education

Harvard Business School, Harvard Graduate School of Arts and Sciences

Boston, MA

PhD Health Policy (Management)

2026 (expected)

Dissertation title: "Prescription Drugs: Innovation, Payment, and Prescribing"

University of Oxford Oxford Oxford, United Kingdom

MPhil Economics, Marshall Scholarship (2018) 2020

Thesis title: "Contracting Pay-for-Performance in the NHS"

Massachusetts Institute of Technology Cambridge, MA

BS Economics 2018

References

Leemore Dafny (Chair)

Amitabh Chandra

ldafny@hbs.edu

achandra@hbs.edu

Leila Agha Mark Shepard

<u>agha@hcp.med.harvard.edu</u> <u>mark_shepard@hks.harvard.edu</u>

Research interests

Fields: Health economics, health policy, innovation economics, *Topics:* Pharmaceutical industry, antitrust and competition policy

<u>Job Market Paper</u> "Policy Incentives and Pharmaceutical Innovation," with Edward Kong <u>Link to latest draft</u>

> Abstract: Pharmaceutical firms' incentives to develop new drugs stem from expected profitability. We explore how policies that shape these expectations influence pharmaceutical innovation. First, we estimate the effects of extending market exclusivity for antibiotics, a drug class where private returns to development historically had not internalized the high social value of new innovation. Using a difference-in-differences approach implementation of legislation that approximately doubled the market exclusivity period for certain antibiotics, we find that the policy increased innovative activity at multiple stages of drug development, from patenting to preclinical activity to phase 3 clinical trials. Building on these empirical findings, we calibrate a structural model of firms' drug development decisions to generalize our findings beyond antibiotics. We simulate counterfactual policies (exclusivity extensions and price controls), highlighting how differences in average market size and revenue timing shape policy effectiveness across therapeutic areas.

Publications

- San Soucie, C, ND Beaulieu, JD Buxbaum, D Cutler, JK Leyenaar, SC McBride, O Zhao, and AT Chien. A National Analysis of General Pediatric Inpatient Unit Closures and Openings, 2011–2018. Hospital Pediatrics 14, no. 11 (November 2024): 899–908. doi: 10.1542/hpeds.2024-007754
- **Zhao O** and AD Sinaiko. Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior. Academy of Management Proceedings. 2024.
- Sinaiko AD, CE Sloan, MJ Soto, O Zhao, C Lin, FR Goss. Clinician Response to Patient Medication Prices Displayed in the Electronic Health Record. JAMA Internal Medicine. 2023;183(10):1172-75. doi:10.1001/jamainternmed.2023.3307
- Vogel M, O Zhao, WB Feldman, A Chandra, AS Kesselheim, BN Rome. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation. JAMA Internal Medicine. 2024;184(1):63-69. doi:10.1001/jamainternmed.2023.6293

Papers Under Review

Zhao O, C San Soucie, DA Rauch, CL Cifra, L Lee, N Beaulieu, D Cutler, and AT Chien. National Trends in Market Competition for Hospital-Based Pediatric Services: 2011-2018

Working Papers

 Kong E and O Zhao. Market Incentives and the Drug Development Pipeline: Evidence from Antibiotics. SSRN Working Paper. 2023. doi:10.2139/ssrn.4676384

Presentations

Southeastern Health Economics Study Group Conference (upcoming)	2025
American Society of Health Economists (ASHE) Annual Conference	2025, 2024, 2023
Boston University Technology & Policy Research Initiative IP Day	2024
Academy of Management Annual Meeting	2024
Health Care Management Division Best Paper Award: "Effects of a Real-Time	
Information-Based Intervention on Physician Prescribing Behavior"	
Pediatric Academic Societies Annual Meeting	2024
NBER Productivity Seminar	2023
Informs Healthcare Conference	2023
AcademyHealth Annual Research Meeting	2023

Professional Service

• Reviewer: Journal of Health Economics

Teaching

Transforming Health Care Delivery MBA, Harvard Business School, Ariel Stern (no rating available)	2024
U.S. Healthcare Industry and Regulatory Policy Masters, Harvard Kennedy School, Leemore Dafny (average rating 4.7/5.0, Distinction in Student Teaching)	2023, 2022

Research in Global Health and Health Policy

Undergraduate, Harvard College, David Cutler
(average rating 4.8/5.0)

Essentials of the Profession (Health Policy module – section co-leader)

MD, Harvard Medical School
(no rating available)

Analytic Frameworks for Public Policy

Masters, Harvard Kennedy School, Richard Zeckhauser

Masters, Harvard Kennedy School, Richard Zeckhauser (average rating 4.8/5.0)

Other research experience

Harvard Business SchoolBoston, MAResearch Assistant to Leemore DafnySep 2020 – Dec 2022Harvard Kennedy SchoolCambridge, MAResearch Assistant to Mark ShepardMay 2021 – Dec 2022Institute for Fiscal StudiesLondon, UKSummer Fellow/Visiting ResearcherMay 2019 – Aug 2020

Other activities

MIT Presidential Committee on Distinguished Fellowships	2021-present
HBS Wyss Awards for Excellence in Mentoring Selection Committee	2022-2025
Health Policy & Management Student Seminar Organizer	2022-2023
HBS Program for Research in Markets & Organizations (PRIMO) Advisor	2023
Health Policy PhD Peer Mentor	2021-2022